Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPA in Hong Kong Oncology Patients Receiving (Neo)-Adjuvant Chemotherapy for Breast Cancer
NCT03386617Phase 2Active, not recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- Feb 2018
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of netupitant + palonosetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by The Chinese University of Hong Kong. Primary endpoints: Complete Response during the delayed phase and Complete Protection during the delayed phase. Started Feb 2018; status: active, not recruiting.
02
Drugs
netupitant + palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT03386617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03386617.